Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Downregulated gene" patented technology

Within the regulation of gene expression, downregulation is the process by which a cell decreases the quantity of a cellular component, such as RNA or protein, in response to an external variable.

Method of down-regulating gene expression

Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.
Owner:IDERA PHARMA INC

Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof

InactiveUS20080161203A1Cure and slow down liver fibrosis progressionSlow curingPeptide librariesHydrolasesCFHR5Biology
In the present invention, the markers identified for liver fibrosis and cirrhosis and the microarray panel thereof comprise at least one of the following proteins / genes:8 up-regulated genes such asANXA2; COL1A2; COL3A1; GSN; LDHB; LUM; PDGFRA and TIMP1.13 down-regulated genes such asALB; ANPEP; APOF; AZGP1; BHMT C8A; CFHR4; CFHR5; COL18A1; FTCD; GYS2; ITIH1, and THRAP1.9 therapeutic targets such as PDGFRA; S100A4; COL3A1; CCL19; DCN; DPT; APP; TNF; and INFG.The present invention is capable of screening markers for the early warning of the occurrence for severe fibrosis or cirrhosis and potentially targets for drug design.
Owner:VITA GENOMICS

Nucleic acids for down-regulation of gene expression

Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.
Owner:UNIVERSITY OF GENEVA +1

Nitroxides for use in treating or preventing amyloid-related diseases

Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of amyloid protein-related diseases. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the amyloid protein-related disease is Alzheimer's disease. In a preferred embodiment, the downregulated genes are genes related to inflammation or oxidative stress.
Owner:MATRIX BIOMED INC

Effect of miR-451a cells in non-small cell lung cancer

The invention relates to the effect of miR-451a cells in the non-small cell lung cancer. Migration of A549 cells can be significantly inhibited through overexpression of miR-451a in the A549 cells. By means of the bioinformatics analysis means, it is predicted that translation of the target gene mRNA is inhibited or the target gene mRNA is directly degraded by miR-451a through regional complementation with 3'-UTR of the target gene CAB39 mRNA; it is determined that the CAB39 gene is the target gene of miR-451a through double-luciferase reporter gene system analysis and Western Blot experiment verification. Finally, it is verified through the Transwell Assay and Flow Cytometry Assay experimental means that miR-451a performs the function of inhibiting migration of cells by reducing the CAB39 gene in the A549 cells, and a novel accurate treating researching and treating scheme is provided. By means of the effect, important research guidance and application value is provided for using miRNA for diagnosing and treating the non-small cell lung cancer and searching for drug targets in the fields such as tumor immunotherapy clinically.
Owner:SHANGHAI UNIV

Modified immunologic effector cell and preparation method thereof

The invention relates to a modified immunologic effector cell. Compared with the expression and / or activity of corresponding genes in corresponding cells that are not modified, the expression and / or activity of a TRAC gene and an HLA-A gene in the invention is down-regulated, the expression and / or activity of a B2M gene is not down-regulated, and the expression and / or activity of the CIITA gene is not down-regulated. The invention also relates to a method for preparing the modified immunologic effector cell.
Owner:宁波茂行生物医药科技有限公司

Application of noble dendrobium total alkali in preparing drug for atherosclerosis

InactiveCN108888713AOvercoming background technical difficultiesCardiovascular disorderPlant ingredientsPharmacometricsBiomedicine
The invention discloses an application of noble dendrobium total alkali in preparing a drug for atherosclerosis and belongs to the technical field of biomedicine. According to the application of nobledendrobium total alkali in preparing the drug for atherosclerosis, the noble dendrobium is biennial noble dendrobium and the dosage of the noble dendrobium total alkali is 20-180 mg / kg per day. The invention further explicits the degreasing action of noble dendrobium total alkali DNLA and a probable action mechanism thereof. By adopting an experimental rat atherosclerosis model and an ApoE- / - mouse transgenic model, influence of the DNLA on hyperlipidemia atherosclerosis of blood vessels is observed, and the action mechanism thereof is analyzed, finding that the DNLA has preventing and treating action on the rat atherosclerosis model and the action mechanism is partially related to down-regulation of expression of MCP-1 / CCR2, MCPIP and CRP genes, thereby providing a basic pharmacologicalbasis for clinical treatment of HLP and As by DENLA.
Owner:ZUNYI MEDICAL UNIVERSITY

Application of reagent for inhibiting or down-regulating expression of GTSE1 gene in preparation of tumor radiotherapy sensitization drug

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.
Owner:GENERAL HOSPITAL OF PLA

Nucleic acids for down-regulation of gene expression

Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.
Owner:UNIVERSITY OF GENEVA +1

SiRNA interfering GDF9 gene expression and application thereof

The invention discloses an SiRNA inhibiting the gene expression of a buffalo growth differentiation factor GDF9, and belongs to the technical field of gene engineering. The positive-sense strand of the siRNA has any sequence indicated by SEQ ID NO: 1-3. The invention also discloses an shRNA encoding gene containing the siRNA and slow virus interference plasmid pshRNA-copGFPLentivector constructed by the same. Through real-time quantitative Real-time PCR (Polymerase Chain Reaction) detection, a relative expression quantity is calculated according to a formula, wherein the buffalo GDF9 mRNA inhibiting efficiencies of two siRNA segments respectively exceed 100%, and the CDF9 protein expression quantity detected by the ELISA (enzyme-linked immuno sorbent assay) is also correspondingly reduced. The siRNA segments and the expression vector thereof can be used to prepare a preparation inhibiting the expression of buffalo GDF9, and can significantly reduce the GDF9 gene expression quantity.
Owner:SOUTH CHINA AGRI UNIV

Application of GPR115 gene in preparation of anti-lung cancer drug and diagnostic kit thereof

The invention discloses application of a GPR115 gene in preparation of an anti-lung cancer drug and a diagnostic kit thereof, and belongs to the technical field of cancer precision medical drugs. Immunohistochemistry proves that the expression of GPR115 in lung cancer is increased through a lung cancer clinical sample tissue chip, and GPR115 is related to prognosis; the influence of down-regulation of GPR115 gene expression by siRNA on biological behaviors such as proliferation and invasion of lung cancer cells is studied through an in-vitro cell experiment, it is found that the specific siRNAsequence can effectively inhibit the expression of GPR115 protein in human lung cancer cell strains H1650 and SPCA, and after the expression of GPR115 is inhibited by siRNA, the proliferation of H1650 and SPCA cells is slowed down, and the cell invasion ability is reduced. The GPR115, as a target for lung cancer gene therapy, can be widely applied to preparation of a diagnostic kit for precisionmedical treatment and treatment of lung cancer with high expression of GPR115.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

SiRNA inhibiting BMP15 gene expression and application thereof

The invention discloses an SiRNA inhibiting the gene expression of buffalo bone morphogenetic protein 15 (BMP15), and belongs to the technical field of gene engineering. The positive-sense strand of the siRNA has any sequence indicated by SEQ ID NO: 1-3. The invention also discloses an shRNA encoding gene containing the siRNA and slow virus interference plasmid pshRNA-copGFPLentivector constructed by the same. Through real-time quantitative Real-time PCR (Polymerase Chain Reaction) detection, people find that siRNA segments can respectively reduce the BMP15 mRNA expression quantity by 29.25%, 57.75%, and 82.5%; and the BMP15 protein expression quantity detected by ELISA (enzyme-linked immuno sorbent assay) detection is also correspondingly reduced. The siRNA segments and the expression vector thereof can be used to prepare a preparation inhibiting the expression of buffalo BMP15, and can significantly reduce the BMP 15 gene expression quantity.
Owner:SOUTH CHINA AGRI UNIV

Method for detecting cadmium pollution through variation of genetic expression of brassica plant

The invention discloses a method for detecting cadmium pollution through variation of genetic expression of a brassica plant. The method comprises steps as follows: extracting total RNA (Ribose Nucleic Acid) from a cadmium-processed brassicajuncea root and a compared brassicajuncea root; hybridizing with a 29K arabidopsis chip, so as to obtain a cadmium induced up-regulated gene and a cadmium induced down-regulated gene under specific expression; designing primers in conserved regions of genes; carrying out a semiquantitative PCR (Polymerase Chain Reaction) method to sieve and determine six up-regulated genes and six down-regulated genes with the specific expression of brassicajuncea when cadmium concentration is more than 1.00mg / kg based on a standard of increasing or reducing 2.00 timesof expression quantity; utilizing variation of gene expression in the root of the brassica plant in primer detection environments of 12 genes; if luminance of a product of the brassica plant in the environment to be detected and amplified by the primers of 6 up-regulated genes is increased over 2.00 times that of contrast, and the luminance of the product of the brassica plant in the environment to be detected and amplified by the primers of 6 down-regulated genes is decreased over 2.00 times that of the contrast, determining that concentration of cadmium in the environment to be detected is more than 1.00mg / kg, thus determining that whether the brassica plant in the environment to be detected is subjected to the cadmium pollution. The detection method is high in sensitivity and high in specificity, and can be used for quickly detecting whether content of the cadmium in the environment of the brassica plant is suitable for agricultural production.
Owner:CENT SOUTH UNIV

Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis

The present disclosure provides methods of treating and / or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and / or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
Owner:THE BROAD INST INC +2

Application of glabridin in preparation of medicine for treating rheumatoid arthritis

The invention provides application of glabridin in preparation of a medicine for treating rheumatoid arthritis. According to the application disclosed by the invention, action mechanism research finds that the glabridin GD can be used for remarkably inhibiting abnormal proliferation of rheumatoid arthritis synovioblasts (RA-FLS), the half inhibition ratio (IC50) of the glabridin GD is lower than 30 micrograms per milliliter, and the glabridin GD has obvious dose-effect and time-effect relationships. The effect of the glabridin in inhibiting the proliferation of the RA-FLS cells is related to the induction of apoptosis, and the glabridin can be used for obviously up-regulating the expression of caspase-3 and caspase-9 genes in the RA-FLS cells and down-regulating the expression of Bcl-2 genes. The glabridin has the potential of being developed into rheumatoid arthritis treatment medicine preparations with good curative effect and high safety and has comprehensive development and application prospects.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

siRNA (small interfering RNA) for inhibiting expression of porcine Somatostatin receptor 2

The invention discloses a siRNA for inhibiting expression of a porcine Somatostatin receptor 2, belonging to the technical field of genetic engineering. The siRNA sense strand provided by the invention has any sequence shown in the SEQID NO:1-3. The invention further discloses shRNA coding genes containing the siRNA and lentivirus interfering plasmids pshRNA-copGFPLentivector constructed with theshRNA coding genes. Through the real-time quantitative Real-time PCR (Polymerase Chain Reaction) examination, it is found that the expression level of a porcine Somatostatin receptor 2mRNA can be remarkably reduced by about 70% above with each siRNA segment and the expression level of SSTR 2 proteins can be reduced by 30% above in ELISA (Enzyme Linked Immunosorbent Assay) examination. The siRNA segment provided by the invention and expression vectors thereof can be used for preparing preparations of inhibiting the porcine Somatostatin receptors 2 and can be used for remarkably reducing the expression level of the SSTR2 (porcine Somatostatin Receptor 2) genes.
Owner:SOUTH CHINA AGRI UNIV

Gene blocking method

The invention relates to methods of regulating gene expression, e.g., to turn on or off, or up or down gene expression in an organism when and where desired, without the toxic side effects usually associated with other contemporary methods, such as those toxic side effects caused by introducing compounds that do not naturally occur in life.
Owner:CALIFORNIA INST OF TECH

Method for increasing saccharification efficiency of plants by down-regulating UXT (UDP-Xylose transporter) gene and application of method

The invention discloses a method for increasing saccharification efficiency of plants by down-regulating a UXT (UDP-Xylose transporter) gene and an application of the method and belongs to the field of biomass energy. According to the method, the saccharification efficiency of the plants is increased by eliminating functions of the UXT gene or down-regulating the UXT gene. By means of the method, xylose content is reduced, relative cellulose content is increased correspondingly, by means of xylose content reduction, the saccharification efficiency of a mutant material is increased and the material disposal cost is reduced. Therefore, biomass characteristics of the material are changed fundamentally, the saccharification efficiency is increased radically, energy can be saved, and labor intensity can be reduced. The material obtained with the method can be applied to biomass transformation, pulp and papermaking industries.
Owner:SOUTH CHINA AGRI UNIV

Application of Guizhou black goat lambing major genes, primer pairs and kit

The invention discloses application of Guizhou black goat lambing major genes, primer pairs and a kit. The Guizhou black goat lambing major genes comprise up-regulation genes AMH, CYP19A1, FOXL2, FSHR, GATA4, INHBA, LHB, LHX9 and ZP3, and down-regulation genes CNOT1, DMRTA1, GHRHR, Hox-All, Oviductin, PCYT1B, SLC34A2, WDR19 and Wnt-7A; and the expression quantity of the up-regulation genes and the expression quantity of the down-regulation genes in the lambing Guizhou black goats are up-regulated and down-regulated respectively. Guizhou black goat lambing major genes are mastered, gene individuals with single-lambing property are gradually eliminated in generation breeding, gene individuals with lambing property are selected and reserved, and an important scientific basis is provided for building a new specialized lambing strain of a breeding group of the Guizhou black goats. The Guizhou black goat lambing major genes, the primer pairs and the kit has an important value for researching the polyfetal character of the Guizhou black goats, and has an important significance for improving the production performance, the breeding supply capacity, the economic benefit and the social benefit of the Guizhou local variety goats.
Owner:贵州省种畜禽种质测定中心

Biological information determination method and system, storage medium and terminal

The invention belongs to the technical field of biological information determination, and discloses a biological information determination method and system, a storage medium, and a terminal. The method comprises the following steps: screening of differentially-expressed genes of pancreatic cancer; GO analysis of the differentially-expressed genes of pancreatic cancer: respectively carrying out GOannotation and graphical display on the obtained differentially-expressed up-regulation and down-regulation genes; KEGG analysis of the differentially-expressed genes of pancreatic cancer: respectively carrying out pathway enrichment and network diagram display on the differentially-expressed up-regulation and down-regulation genes; and PPI interaction network analysis of the differentially-expressed genes and core genes of pancreatic cancer to determine a signal transduction pathway of the differentially-expressed genes. According to the invention, a bioinformatics means is adopted to screenthe differentially-expressed genes of pancreatic cancer and a signal transduction pathway of the differentially-expressed genes, and a molecular mechanism of the occurrence and development of pancreatic cancer is disclosed, so a theoretical basis is provided for early diagnosis and prevention of pancreatic cancer, and an effective target is provided for treatment of pancreatic cancer.
Owner:DEZHOU UNIV

Lung adenocarcinoma related diagnostic marker and application thereof

The invention discloses a lung adenocarcinoma related diagnostic marker and an application thereof. The diagnostic marker is used for encoding IL1F5 protein and encoding mRNA of the IL1F5 protein. PCRdetection and tissue chip immunohistochemistry of a clinical lung adenocarcinoma sample prove that the expression of IL1F5 in the lung adenocarcinoma is increased, and survival analysis shows that the prognosis of a patient with higher expression of the IL1F5 is poorer. Influence of down-regulation of the IL1F5 gene expression by siRNA on biological behaviors such as lung adenocarcinoma cell proliferation and invasion is studied through in-vitro cell experiments, and it is found that a specific siRNA sequence can effectively inhibit expression of the IL1F5 protein in a human lung adenocarcinoma cell strain H1299. Under the condition of co-cultivation with CD8+T cells, the proliferation and invasion capacities of H1299 cells with reduced IL1F5 expression are reduced (no difference exists when the tumor cells are cultured alone).
Owner:JIANGSU CANCER HOSPITAL

Construction method of recombinant adeno-associated virus vector of targeting interference SOCS1 gene and application of construction method

The invention belongs to the biomedical field and relates to a construction method of a shRNA (short hairpin RNA, shRNA) recombinant adeno-associated virus vector for specially restraining SOCS1 gene expression and an application of the construction method. The shRNA recombinant adeno-associated virus vector is transferred to a monocyte-macrophage-dendritic cell system for lowering the SOCS1 gene expression and strengthening the anti-tumor activity of CTL (Cytotoxic T Lymphocyte). Therefore, the construction method can play an important role in the biomedical field and the research of gene function, can be used for preparing anti-tumor dugs and is high in clinical application value.
Owner:吕成伟

Application of DCUN1D1 gene to control of vitiligo

The invention provides an application of a DCUN1D1 gene to control of vitiligo. Through research, the applicant finds that the DCUN1D1 gene expression of a patient suffering from vitiligo is increased, and experimentation on animals confirms that specific overpression of DCUN1D1 on keratinocyte can enable local facial depigmentation of mice, growth of hair follicles is restrained, the skin thickness is thinned, and chromogenesis in the hair follicles is restrained. The DCUN1D1 gene is promoted to be a new target point of medicines for treating vitiligo, the expression of the DCUN1D1 gene is reduced to promote proliferation of the keratinocyte, reduce apoptosis and promote melanocyte migration, and the application is a new way of treatment with medicines. The application has the beneficialeffects that the new gene target point for treatment of vitiligo is found, a new purpose of a DCUN1D1 gene inhibitor to preparation of medicines for treating facial depigmentation particularly medicines for treatment of vitiligo is provided, and a foundation is provided for screening of new medicines.
Owner:HANGZHOU THIRD HOSPITAL

Application of SFN (sulforaphane) to preparation of medicine for treating leukemia

The invention discloses application of SFN (sulforaphane) to preparation of medicine for treating leukemia, and belongs to the technical field of novel purpose of the SFN. The application is characterized in that according to the application of the SFN to the preparation of the medicine for treating the leukemia, the SFN promotes the leukemia apoptosis through raising Bax genes and Caspase-3 genes and reducing Bcl-2 genes for further inhibiting the multiplication of leukemia cells. The influence of the SFN on the acute leukemia cell KG1a and K562 apoptosis is systematically discussed for the first time; a result proves that the SFN can promote the acute leukemia apoptosis through regulating and controlling the Bax genes, the Bcl-2 genes and the Caspase-3 genes; the result belongs to the theoretical breakthrough and has the potential clinic application significance; a fire-new thought and potential treatment path is provided for leukemia treatment.
Owner:XINXIANG MEDICAL UNIV +1

siRNA that inhibits porcine somatostatin receptor 2 gene expression

The invention discloses a siRNA for inhibiting expression of a porcine Somatostatin receptor 2, belonging to the technical field of genetic engineering. The siRNA sense strand provided by the invention has any sequence shown in the SEQID NO:1-3. The invention further discloses shRNA coding genes containing the siRNA and lentivirus interfering plasmids pshRNA-copGFPLentivector constructed with theshRNA coding genes. Through the real-time quantitative Real-time PCR (Polymerase Chain Reaction) examination, it is found that the expression level of a porcine Somatostatin receptor 2mRNA can be remarkably reduced by about 70% above with each siRNA segment and the expression level of SSTR 2 proteins can be reduced by 30% above in ELISA (Enzyme Linked Immunosorbent Assay) examination. The siRNA segment provided by the invention and expression vectors thereof can be used for preparing preparations of inhibiting the porcine Somatostatin receptors 2 and can be used for remarkably reducing the expression level of the SSTR2 (porcine Somatostatin Receptor 2) genes.
Owner:SOUTH CHINA AGRI UNIV

Method for determining up-regulated genes and down-regulated genes in cotton fiber development process

The invention provides a method for determining up-regulated genes and down-regulated genes in a cotton fiber development process. The method includes the steps: acquiring a first transcriptome and a second transcriptome from samples of cotton fibers in a first development stage and a second development stage respectively, and sequencing to obtain sequencing data of the first transcriptome and sequencing data of the second transcriptome; respectively performing primary assembling based on the sequencing data of the first transcriptome and the sequencing data of the second transcriptome to obtain first primary assembling data and second primary assembling data; merging the first primary assembling data and the second primary assembling data, and using overlapped primary genes in the first primary assembling data and the second primary assembling data to perform secondary assembly for acquiring secondary assembling data; performing tertiary assembling on the basis of an overlapping relation between the secondary assembly data and reference genes to obtain tertiary assembling data; calculating expression quantities, in the two samples, of tertiary genes in the tertiary assembling data, acquiring differentially expressed genes according to the condition whether difference of the expression quantities is significant or not, and determining the up-regulated genes and down-regulated genes in the cotton fiber development process.
Owner:XINJIANG AGRI UNIV

Cytotoxic T lymphocytes with CA9 tumor antigen specificity

InactiveCN111560351AEnhanced Kidney Cancer TargetingImprove targetingGenetically modified cellsPeptidesT lymphocyteT cell
The invention provides a preparation method of renal cell carcinoma tumor antigen CA9 specific cytotoxic T lymphocytes, which comprises the following steps: infecting mature DC cells with a recombinant vector containing siRNA targeting SOCS1 and carbonic anhydrase 9 to obtain iSOCS1-CA9-DC cells; and then carrying out mixed culture on the iSOCS1-CA9-DC cells and T cells to obtain CA9-DC-CTL cells,namely the cytotoxic T lymphocytes with antigen specificity. According to the invention, replication-defective adenovirus mediated RNAi is adopted to down-regulate SOCS1 gene expression, and CA9 andS-Flagellin are combined to stimulate DC cell maturation so as to induce specific CTL to resist renal cell carcinoma. The targeting property of CTL to kidney cancer cells is effectively enhanced, damage to autologous cells is avoided, growth of tumors can be effectively inhibited, and the lifetime of a patient is prolonged.
Owner:山东省齐鲁细胞治疗工程技术有限公司

Novel pharmaceutical application of apatinib or pharmaceutically acceptable salt thereof

The invention relates to a novel pharmaceutical application of apatinib or a pharmaceutically acceptable salt thereof, in particular to an application of apatinib or a pharmaceutically acceptable saltthereof in preparation of a medicine for treating malignant mesothelioma. The in-vitro test result shows that apatinib mesylate inhibits MPM cell proliferation and activity, affects the G2 / M phase ofthe MPM cell cycle process and remarkably inhibits MPM cell movement and migration; an in-vivo test result shows that the apatinib mesylate obviously reduces the ePCI score and has no influence on the body weight of nude mice. The apatinib has no histological toxicity to lung, spleen, kidney and gastrointestinal tract, only has focal lymphocyte infiltration in liver and myocardial tissues, and has an obvious effect of down-regulating NPM2 gene expression. The new application of apatinib or the pharmaceutically acceptable salt thereof provided by the invention provides an important theoreticalbasis for application of apatinib or the pharmaceutically acceptable salt thereof in treatment of malignant mesothelioma, widens the treatment range of the drug, and provides a new drug solution fortreatment of malignant mesothelioma.
Owner:BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products